Back to discover
Drug

Aprepitant

Approved · FDA / EMA
Emerging researchLate-stage developmentRising momentum

Also known as Aponvie, Cinvanti, Emend, Aprepitantum.

RxNorm358255ChEMBLCHEMBL1471UNII1NF15YR6UY
3
Research papers
8
Active clinical trials
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

A Pilot Feasibility Study of a Steroid-Sparing Anti-Nausea and Vomiting Regimen With Netupitant/Palonosetron for Patients With Germ Cell Tumours Receiving Multi-Day Cisplatin-Based Chemotherapy at The Ottawa Hospital

Clinical trial2026-06-23Results expected Q3 2027 · ClinicalTrials.gov

Approval: APREPITANT (NDA218754)

Regulatory2026-06-16FDA

Preoperative Aprepitant to Improve Same-Day Discharge After Total Knee Arthroplasty: A Randomized Double-Blind Placebo-Controlled Trial

Clinical trial2026-06-10Results expected Q3 2027 · ClinicalTrials.gov

Randomized, Embedded, Multifactorial Adaptive Platform for Perioperative Medicine at UPMC (UPMC REMAP): Core Protocol - Enhanced Recovery Protocols (ERP)

Clinical trial2026-05-28Results posted · ClinicalTrials.gov

A Randomized Controlled Trial Comparing Aprepitant to Standard of Care for Postoperative Nausea and Vomiting Prophylaxis in Children and Adolescents Undergoing Scoliosis Surgery: The APRE-PONV Trial

Clinical trial2026-04-27Results expected Q1 2027 · ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection in the Prevention of Post-operative Nausea and Vomiting

Clinical trial2026-03-28Primary completion · ClinicalTrials.gov

A Phase 2 Open-Label Study of HTX-011 Via Individualized Dosing Administration for Postoperative Analgesia Following Unilateral Simple Bunionectomy

Clinical trial2026-03-02Results posted · ClinicalTrials.gov

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.

Research2016-03-17European journal of cancer (Oxford, England : 1990)

Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.

Research2012-08-20Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Research2009-07-01Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Approval: Emend (EMA)

Regulatory2003-11-11EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Aprepitant
Aliases & brands
AponvieCinvantiEmendAprepitantum
RxNorm CUI
358255
ChEMBL ID
CHEMBL1471
UNII
1NF15YR6UY
Regulatory jurisdictions
fdaema

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2003-11-11
Latest approval
2026-06-16
Authorities
FDA · EMA
Total events
2
fdaU.S. Food and Drug Administration· 1 event
2026-06-16Approval
Approval: APREPITANT (NDA218754)
Evidence ↗
emaEuropean Medicines Agency· 1 event
2003-11-11Approval
Approval: Emend (EMA)
Indication: Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the… Show full indication

Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics). Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults. Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years. Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.

Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

125 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
125
registered trials across all phases
LATEST COMPLETION 2025
8
Active studies
8
Recruiting
82
Late-stage (III+)
86
Completed
31
Discontinued
PHASE DISTRIBUTIONn = 125
Early Phase 12Phase 114Phase 1 / 22Phase 225Phase 2 / 31Phase 330Phase 423Phase N / A28

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial

Not yet recruitingPH IVKey trialSecond Affiliated Hospital, School of Medicine, Zhejiang Universityn=1,0282029

Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery: A Pilot Randomized-Controlled Trial

Not yet recruitingPH IVSir Mortimer B. Davis - Jewish General Hospitaln=1002028

Preoperative Aprepitant to Improve Same-Day Discharge After Total Knee Arthroplasty: A Randomized Double-Blind Placebo-Controlled Trial

Not yet recruitingPH IVEndeavor Healthn=3502027

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

CompletedPH IVYale Universityn=462025

Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery: a Prospective, Randomised, Placebo-controlled, Triple-blind, Single Centre Trial.

TerminatedPH IVInsel Gruppe AG, University Hospital Bernn=712025

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized, Double-blind, Placebo-controlled Clinical Study on Prevention and Treatment of CINV Induced by TC Regimen in Gynecological Malignant Tumors

CompletedPH IIISichuan Cancer Hospital and Research Instituten=1432025

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

CompletedPH IVYale Universityn=462025

Randomized, Embedded, Multifactorial Adaptive Platform for Perioperative Medicine at UPMC (UPMC REMAP): Core Protocol - Enhanced Recovery Protocols (ERP)

CompletedPH IIIKey trialJennifer Holder-Murrayn=3,3952025

Clinical Study of Aprepitant and Ondansetron Monotherapy or Combination in the Treatment of Postoperative Nausea and Vomiting in Thyroid Carcinoma

CompletedPH IVThe First Affiliated Hospital of Zhengzhou Universityn=6002025

Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.

CompletedPH IIIUniversity Hospital, Brestn=632024

A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Aprepitant Injection(QLG2174) in the Prevention of Post-operative Nausea and Vomiting

CompletedPH IIIQilu Pharmaceutical (Hainan) Co., Ltd.n=5182024

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20102016
Most influential

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010 · 169 cites

Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012 · 72 cites

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.

European journal of cancer (Oxford, England : 1990) · 2016 · 4 cites
Recent papers

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study.

European journal of cancer (Oxford, England : 1990) · 2016 · 4 cites

Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2012 · 72 cites

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2010 · 169 cites
Journals, researchers & institutions
Top journals
  • European journal of cancer (Oxford, England : 1990)1
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
  • Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer1
Leading researchers
  • Albany C1
  • Angulo Mdel M1
  • Boice JA1
  • Brames MJ1
  • Brown C1
  • Calvo L1
  • Cámara MC1
  • Carañana V1
Leading institutions
free-text, unnormalised
  • Complejo Hospitalario Universitario A Coruña1
  • Hospital Arnau de Vilanova de Lleida1
  • Hospital Arnau de Vilanova de Valencia1
  • Hospital Clinic i Provincial1
  • Hospital Clínico San Carlos1
  • Hospital Clínico Universitario Lozano Blesa1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.